While the typical delayed gadolinium enhancement seen on cardiac MRI represents sarcoid inflammation related cardiac damage and scarring, FDG uptake represents active inflammation. Both FDG PET and MRI provide high sensitivity for diagnosing cardiac sarcoidosis, but the specificity of cardiac MRI is better. 12 Advantages of FDG PET include the biologic nature of the imaging signal, the ability to identify cardiac and extracardiac sarcoidosis involvement in one exam, feasibility of imaging patients with electrical/metallic devices and renal impairment, assessment of therapy response and risk stratification. 7, 13, 14 In the present issue of the Journal of Nuclear Cardiology, Patel and colleagues from the University of Illinois, Chicago, investigate the relationship of extrathoracic sarcoid findings in patients with cardiac sarcoidosis using FDG PET-CT, performed after a 72-hour high fat, high protein, and very low carbohydrate (HFHPVLC) diet. 15 Their aim was to determine if sarcoid patients being evaluated for cardiac involvement would benefit from whole body FDG PET-CT imaging (skull base to thighs) versus the limited thoracic imaging offered by cardiac MRI. A total of 191 consecutive FDG PET-CT scans were reviewed, of which 20 scans (10%) were positive and six scans indeterminate (3%) for CS. Of the 20 CS positive scans, 12 (60%) were negative for extrathoracic sarcoid findings and 8 (40%) showed extrathoracic involvement. Also, of the 165 scans (86%) that were negative for CS, 56 (34%) were positive for extrathoracic sarcoid involvement. Their findings make a persuasive argument in favor of whole body FDG PET-CT for diagnosis of not only cardiac sarcoidosis, but also extrathoracic sites of involvement, which cannot be assessed with the limited field of view cardiac MRI. Additionally, while MRI has the advantage of providing dual structural and functional information, its spatial resolution in the lungs is inferior to CT, 16 Patient preparation plays an extremely important role in determining cardiac FDG PET image quality. Numerous preparation protocols aimed at suppressing physiologic myocardial glucose utilization/FDG uptake have been described without a clear consensus on the optimal method. A 1-2 meal high fat, high protein, low to no carbohydrate diet followed by at least 4-hours of fasting, with or without intravenous heparin (50 IU/kg) 15-minutes prior to FDG injection, have been shown to be successful in suppressing physiologic myocardial FDG uptake in 85%-100% of cases.
14,17-21 Patel and colleagues prepared their patients with a 72-hour HFHPVLC diet protocol that included breakfast approximately 4 hours before scanning, and were able to successfully suppress background myocardial FDG uptake and minimize indeterminate findings. 15 Previously their group had proven effectiveness and high compliance rates using the same dietary preparation method. 22 Similar to their prior publication, the authors report an impressive indeterminate rate of 3% and only three patients excluded from the study due to diet nonadherence, again validating its effectiveness and high compliance rate.
With regards to scan interpretation, Patel and colleagues visually classified the myocardial FDG uptake patterns into: Negative for CS (''none'' and ''ring-like diffuse activity at base''), Positive for CS (''focal'' uptake), and Indeterminate for CS (including ''diffuse'' and ''focal on diffuse''). 15 Other methods of image interpretation and pattern classification have been described, however until the recent publication of the 'Joint SNMMI-ASNC Expert Consensus Document on the Role of FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring,' none were formally established or validated with histological findings, 23, 24, 25 thus setting up for inconsistent image interpretation. For example, while diffuse myocardial FDG uptake has been described as a normal variant by some investigators, 12, 26, 27 Patel et al. categorize this finding as ''indeterminate''. 15, 22 There is also the mystery of FDG uptake in the lateral wall and ring-like diffuse activity at the heart base seen in some normal/healthy individuals. 23, 27 Moreover, Patel et al. make no reference to myocardial perfusion during image interpretation, which is considered important and essential by most practitioners. 23 For example Blankstein and colleagues have put forth the following interpretation patterns; normal perfusion and metabolism, abnormal perfusion or metabolism and abnormal perfusion and metabolism. 14 Okumura and colleagues have also shown the capability of FDG PET to detect early stage of cardiac sarcoidosis, in which fewer perfusion abnormalities and high inflammatory activity are noted. They proposed the following pathophysiologic classification, based on myocardial perfusion and FDG uptake patterns: ''Normal'' (normal perfusion/normal FDG uptake), ''Early Stage'' (no perfusion defect/increased FDG uptake), ''Progressive Inflammatory Stage'' (mild perfusion defect/ increased FDG uptake), ''Peak Active Stage (moderate perfusion defect/increased FDG uptake), ''Progressive Myocardial Impairment Stage'' (severe perfusion defect/increased FDG uptake), and ''Fibrosis Stage'' (severe perfusion defect/ minimal or no FDG uptake). 28, 29 Further research correlating imaging findings with histology is needed. The recently published 'Joint SNMMI-ASNC Expert Consensus Document on the Role of 18 F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring' is a comprehensive document that discusses the indications for cardiac PET/ CT for disease detection and management; provides recommendations on image acquisition, processing, and interpretation; and also reviews clinical scenarios in which PET/CT may help guide patient management. For image interpretation it recommends a normalized approach which involves simultaneous interpretation of perfusion and FDG images where the intensity of each image on perfusion and FDG is normalized to the maximum counts per pixel. 25 Although not the focus of their study, Patel et al. make reference to the added benefit of treatment monitoring with FDG PET-CT by including example images of a case study of disease progression after 17-month steroid therapy that prompted change in treatment. 15 FDG PET can be used to assess treatment response/ disease activity not only visually but also objectively by using different quantitative techniques. 13, 30, 31 Ahmadian and colleagues nicely demonstrate that visual interpretation of FDG PET-CT images in cardiac sarcoidosis is less sensitive than quantitative measures (cardiac metabolic volume, cardiac metabolic activity and maximum standardized uptake value) for the assessment of response to immunosuppressive treatment. 32 They also observed a rebound in quantitative FDG parameters after cessation of immunotherapy and acknowledge that reduction in the FDG signal has not been definitively proven to alter the disease progression or natural history of cardiac sarcoidosis. Although in a retrospective study, Yamagishi et al. describe seven patients diagnosed with cardiac sarcoidosis based on the Japanese Ministry of Health and Welfare guidelines that were treated with corticosteroids and underwent a cardiac 13 NitrogenAmmonia/ 18 F-FDG PET a month later. While 13 Nitrogen-Ammonia myocardial perfusion defects exhibited no significant change, the FDG uptake was markedly diminished in size and intensity in five patients and disappeared completely in two patients. Furthermore, three of these patients demonstrated improvements and/or disappearance of conduction abnormalities or ventricular tachycardia. 33 In addition, preliminary data by the University of Pennsylvania investigators has also shown that metabolic active volume and total lesion glycolysis are promising imaging biomarkers to evaluate disease progression. 34 Prospective studies are needed to determine if quantitative changes in FDG uptake are associated with improved outcomes. Besides, an interval decrease in myocardial FDG uptake should be interpreted carefully and in combination with perfusion imaging, since it can represent not only treatment response but also postinflammatory scarring and fibrosis. 29 The metabolic alterations related to prolonged corticosteroid therapy can also make performing and interpreting FDG images challenging. Elevations in serum glucose and insulin levels due to corticosteroid use may adversely affect FDG uptake by normal myocytes and reduce test specificity. 29 In closing, while FDG PET is a powerful imaging technique for the diagnosis, prognosis and management of cardiac sarcoidosis there are several challenges and unanswered questions. Some of these include the lack of consensus on an optimal patient preparation method, the unclear association between disease outcome and treatment related visual and/or quantitative changes in FDG uptake, the incomplete suppression of physiologic myocardial FDG uptake in a small proportion of studies (10%-15%) despite all interventions, 35 prompting the need for an alternative/more specific inflammation imaging radiotracer etc. Clearly there is a lot more to learn. Until then, Patel and colleagues provide us with more evidence of the effectiveness of the 72-hour HFHPVLC diet preparation and make a strong case for whole body FDG PET-CT imaging over cardiac MRI to evaluate both cardiac and extracardiac burden of sarcoidosis.
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